Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03211013 · ClinicalTrials.gov registry record · Early Phase 1
Study of the Effects of Oxytocin on Attentional Bias and Startle in PTSD
A Early Phase 1 study, sponsored by Palo Alto Veterans Institute for Research.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 17
- Enrollment target
NCT03211013 is a Early Phase 1 study that has completed, run by Palo Alto Veterans Institute for Research. The registered enrollment target is 17 participants.
The verdict
NCT03211013, a Early Phase 1 study, has completed, sponsored by Palo Alto Veterans Institute for Research.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 17 participants
- Enrollment target
Study Summary
The investigators will test whether intranasal oxytocin (24 IU vs placebo) will induce effects on attention bias and startle comparable to those the investigators have shown to be induced by the presence (vs absence) of a service dog in Veterans diagnosed with PTSD. This possibility is suggested by a 2015 study showing that urinary oxytocin levels are elevated in association with mutual gaze between dogs and their owners.
Interventions
- DRUG Oxytocin
- DRUG Placebos
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2017-07-10 |
| Est. Completion | 2021-06-09 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03211013
The ClinicalTrials.gov registry entry for NCT03211013 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Palo Alto Veterans Institute for Research, which has 35 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Oxytocin is the first listed.
NCT03211013 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03211013 about?
NCT03211013 is a clinical study titled "Study of the Effects of Oxytocin on Attentional Bias and Startle in PTSD". The investigators will test whether intranasal oxytocin (24 IU vs placebo) will induce effects on attention bias and startle comparable to those the investigators have shown to be induced by the presence (vs absence) of a service dog in Veterans diagnosed with PTSD. This possibility is suggested by ...
What is the current status of trial NCT03211013?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 17 participants. The study started on 2017-07-10. Estimated completion is 2021-06-09.
What interventions are being tested in trial NCT03211013?
The interventions under investigation include: Oxytocin (DRUG), Placebos (DRUG).
Who is sponsoring clinical trial NCT03211013?
This trial is sponsored by Palo Alto Veterans Institute for Research, which has 35 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.